Kangchen Pharmaceutical (603590.SH): Phase II clinical study of KC1086 combined with fluviztine to treat breast cancer completed the first patient enrollment

Zhitongcaijing · 4d ago

Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) announced that recently, KC1086 tablets (“KC1086” for short) independently developed by the company successfully completed the first case of the “KC1086 combined with fluorovisgroup for HR+/HER2- Locally Advanced or Metastatic Breast Cancer Phase II Clinical Study (KC1086-COM-01)”.

Test name: Phase II clinical study to evaluate the safety, efficacy and pharmacokinetic characteristics of KC1086 combined with fluvirizin in patients with positive hormone receptor (HR+) and negative human epidermal growth factor receptor 2 (HER2-) locally advanced or metastatic breast cancer.